and Disqualification Recommendations for Competitive Athletes With
Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy,
Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and
Myocarditis: A Scientific Statement From the American Heart Association and
American College of Cardiology
Barry J. Maron, James E. Udelson, Robert
O. Bonow, Rick A. Nishimura, Michael J. Ackerman, N.A. Mark Estes III, Leslie
T. Cooper, Jr, Mark S. Link, Martin S. Maron, and on behalf of the American
Heart Association Electrocardiography and Arrhythmias Committee of the Council
on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council
on Cardiovascular and Stroke Nursing, Council on Functional Genomics and
Translational Biology, and the American College of Cardiology
Circulation. 2015; published online
before print November 2 2015, doi:10.1161/CIR.0000000000000239
The American Heart Association and
American College of Cardiology have released a series of scientific statements
regarding eligibility and disqualification recommendation for competitive
athletes with cardiovascular abnormalities. This is the 4th document of 15
scientific statements. “Hypertrophic cardiomyopathy (HCM) is a major focus of this
document given that it is the single most common cause of sudden death.” The
document includes recommendations throughout.